Poly(ADP-ribose) Glycohydrolase (PARG) Assay Service
Background Service Workflow Highlights FAQs Contact Us
At Creative Biolabs, our PARG Assay Service provides in-depth profiling of PARG activity, inhibitor evaluation, and immune signaling assessment in cancer systems, enabling clients to study this underexplored yet critical regulatory enzyme.
Background
Poly(ADP-ribose) glycohydrolase (PARG) is the principal enzyme responsible for degrading poly(ADP-ribose) (PAR) chains synthesized by PARPs. It plays a critical role in regulating PARylation dynamics and ensuring controlled resolution of DNA repair. In the tumor microenvironment, aberrant PARG activity can suppress DNA damage–associated immune signals, modulate cGAS-STING pathway responses, and influence tumor immunogenicity. PARG inhibition has been shown to enhance anti-tumor immunity, synergizing with checkpoint blockade and DNA-damaging agents.
Featured Services at Creative Biolabs
Our assay solutions support the analysis of PAR degradation and its immunological implications across in vitro and cellular models:
Fluorogenic PARG Activity Assay
Real-time monitoring of PAR cleavage using fluorescently labeled PAR substrates for kinetic profiling
Colorimetric Detection of PAR Hydrolysis
Quantification of degraded PAR fragments using absorbance-based assays compatible with high-throughput screening
Radioisotope-Based PARG Assay
Sensitive detection of [³²P]-labeled PAR chain degradation products for precision enzyme kinetics
Cell-Based PAR Turnover Monitoring
Evaluate PARG function in tumor cells following genotoxic insult, with downstream readouts for immune priming
STING Pathway Coupled Analysis
Assessment of PARG's impact on cytosolic DNA accumulation, cGAS-STING pathway activation, and interferon signaling
Custom Inhibitor Screening Platform
High-throughput profiling of PARG inhibitors with target specificity, potency, and immune biomarker readouts
Workflow
Highlights
-
Focused on DNA Damage–Immune Signaling Axis – Analyze how PARG regulates immune sensor activation post-DNA insult
-
Multiple Assay Readouts – Fluorescence, radioactivity, or absorbance tailored to desired resolution and throughput
-
PARG Inhibitor Discovery – Enable identification of novel immunomodulatory compounds for combination immunotherapy
-
Link to Interferon Response – Observe impact of PARG activity on cGAS-STING-mediated IFN production and antigen presentation
-
Flexible Cell Model Integration – Apply to immune-competent, checkpoint-relevant, or STING+ tumor models
FAQs
Q1: What's the difference between PARP and PARG in your assay systems?
A1: PARP builds poly(ADP-ribose) chains, while PARG degrades them. We offer distinct but complementary assay systems to dissect both processes.
Q2: Can PARG inhibition enhance immunogenicity of tumor cells?
A2: Yes. PARG suppression can sustain DNA damage signals, promoting innate immune activation and enhancing tumor recognition.
Q3: Do you support co-treatment assays with DNA-damaging agents?
A3: Absolutely. We can combine PARG inhibition with agents like cisplatin, topotecan, or irradiation to simulate therapeutic stress.
Q4: Is your assay platform adaptable for inhibitor screening?
A4: Yes. We provide high-throughput compatible PARG assays for inhibitor discovery, with IC₅₀ values and immunological endpoints.
Q5: How does PARG inhibition influence interferon gene expression?
A5: We offer transcriptomic and reporter assays to quantify IFN-stimulated gene expression downstream of PARG-modulated pathways.
Harness PARG Biology to Strengthen DNA Damage–Immune Integration
Creative Biolabs provides advanced tools to decipher the immunological implications of PAR chain degradation. Our PARG assay platform empowers discovery of immune modulators and DDR-based combination therapies.
For Research Use Only | Not For Clinical Use
